Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $165
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Hold rating on Quest Diagnostics while raising the price target from $158 to $165.
October 07, 2024 | 12:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has maintained a Hold rating on Quest Diagnostics and increased the price target from $158 to $165, indicating a positive outlook.
The increase in price target from $158 to $165 by Truist Securities suggests a positive outlook for Quest Diagnostics, which could lead to a short-term increase in stock price. However, the Hold rating indicates that the stock may not outperform the market significantly.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100